HOME >> MEDICINE >> NEWS
Primary biliary cirrhosis more prevalent around toxic waste sites in NYC

According to a new study, exposure to toxins from hazardous waste sites may be a significant risk factor for developing primary biliary cirrhosis (PBC). Published in the March 2006 issue of Hepatology, researchers found significant clusters of the disease near Superfund toxic waste sites (SFS) and that the majority of patients in New York City who need liver transplants because of PBC, reside near SFS. Hepatology is published on behalf of the society by John Wiley & Sons, Inc., and is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

PBC is an uncommon liver disease of unknown cause, though it reportedly appears in geographic clusters. Researchers, led by Aftab Ala, M.D. of Mount Sinai School of Medicine in New York City, examined the prevalence and potential clustering of PBC near New York City's most toxic waste sites, which are state-designated SFS.

The researchers collected zip code data on 172 patients in New York City in need of orthotopic liver transplant (OLT) between 1995 and 2003 due to either PBC or primary sclerosing cholangitis (PSC). They compared the patients' zip codes to zip codes of known SFS in the city. Of the city's 174 zip codes, 89 included or bordered SFS and 85 did not.

The researchers then calculated the expected prevalence of PBC-OLT and PSC-OLT, adjusting for demographic characteristics. They compared the mean standardized prevalence ratios in zip codes containing or adjacent to a SFS to the remaining zip codes. Lastly, they utilized SaTScan, a statistical software package, to detect specific clusters.

"The prevalence ratio of PBC-OLT, not PSC-OLT, was significantly higher in zip codes containing or adjacent to SFS," the authors report. The standardized prevalence ratio of PBC-OLT cases near SFS was statistically significantly higher than in zip codes that did not have, nor border with, a toxi
'"/>

Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
1-Mar-2006


Page: 1 2

Related medicine news :

1. Causes of primary biliary cirrhosis
2. Double the death rate from cirrhosis for blue collar men
3. Racial disparities in treatment of patients with cirrhosis and complications of portal hypertension
4. Relative risks of cirrhosis from non-alcoholic steatohepatitis
5. Increase in death rates from liver cirrhosis in Britain largest in western Europe
6. New specially coated non-stick tips stents help keep blood vessels open for cirrhosis patients
7. OPICAN study in seven Canadian cities reveals prescription opioid abuse more prevalent than heroin
8. Under-diagnosed rage disorder more prevalent than previously thought
9. Mild cognitive impairment prevalent in elderly population
10. Experts question prevalent stereotypes about autism
11. Womens silent health problem: Study finds fecal incontinence is prevalent in US women

Post Your Comments:
(Date:6/29/2015)... CA (PRWEB) , ... June 29, 2015 , ... ... and imprinted accessories, is offering discounted pricing on all purchases that include branding. ... foundation of a brand is the logo. The website, packaging and promotional materials, all ...
(Date:6/29/2015)... VA (PRWEB) , ... June 29, 2015 , ... ... services to government contractors, nonprofits, independent schools, and other growing businesses across the ... Insights Top 100 Value Added Resellers for the fifth consecutive year. , Based ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors and Usability Studies: ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors , The ... to the design of new products as well as to postmarket surveillance of ...
(Date:6/29/2015)... , ... June 29, 2015 , ... People across the country give their coworkers and ... part of our culture. , But, how often do coworkers donate “life” to the ... a simple one. , “Dawna (Wright-Thompson) told me her husband was on a ...
(Date:6/29/2015)... ... June 29, 2015 , ... Two ... against C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in New ... Management Conference is to be convened on Thursday, July 23rd at 12:00 p.m. ...
Breaking Medicine News(10 mins):Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4
(Date:6/29/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... is now included in the Russell 3000®, the Russell ... to the indexes occurred at the close of trading ... its comprehensive set of U.S. and global indexes. ... Cap and Global Indexes coincides with the progress we ...
(Date:6/29/2015)... , June 29, 2015  Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced ... study with novel formulations of oral, enteric-coated buprenorphine ... chronic pain and opioid dependence indications has reached ... company anticipates reporting top-line results in the second ...
(Date:6/29/2015)... England , June 29, 2015  Eli ... Immunocore Limited today announced that they have entered ... the utility of Immunocore,s lead T cell receptor-based ... (LY2157299) and merestinib (LY2801653) for the treatment of ... identify combination regimens that provide synergies in efficacy ...
Breaking Medicine Technology:Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 2Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 3Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 2Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 2Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 4Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 5Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 6Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 7
Cached News: